全文获取类型
收费全文 | 1017421篇 |
免费 | 76301篇 |
国内免费 | 8522篇 |
专业分类
耳鼻咽喉 | 13596篇 |
儿科学 | 25167篇 |
妇产科学 | 24190篇 |
基础医学 | 143229篇 |
口腔科学 | 29807篇 |
临床医学 | 93255篇 |
内科学 | 195788篇 |
皮肤病学 | 19914篇 |
神经病学 | 77285篇 |
特种医学 | 39883篇 |
外国民族医学 | 135篇 |
外科学 | 160041篇 |
综合类 | 33255篇 |
现状与发展 | 23篇 |
一般理论 | 247篇 |
预防医学 | 67338篇 |
眼科学 | 24217篇 |
药学 | 81536篇 |
105篇 | |
中国医学 | 7953篇 |
肿瘤学 | 65280篇 |
出版年
2021年 | 10697篇 |
2019年 | 9096篇 |
2018年 | 12335篇 |
2017年 | 9851篇 |
2016年 | 10530篇 |
2015年 | 13090篇 |
2014年 | 17172篇 |
2013年 | 21880篇 |
2012年 | 30504篇 |
2011年 | 32491篇 |
2010年 | 19292篇 |
2009年 | 17780篇 |
2008年 | 29068篇 |
2007年 | 30043篇 |
2006年 | 31007篇 |
2005年 | 29988篇 |
2004年 | 27242篇 |
2003年 | 26225篇 |
2002年 | 25311篇 |
2001年 | 56540篇 |
2000年 | 58483篇 |
1999年 | 49008篇 |
1998年 | 12136篇 |
1997年 | 10796篇 |
1996年 | 10678篇 |
1995年 | 9923篇 |
1994年 | 9108篇 |
1993年 | 8117篇 |
1992年 | 36066篇 |
1991年 | 34396篇 |
1990年 | 33177篇 |
1989年 | 32271篇 |
1988年 | 29324篇 |
1987年 | 28513篇 |
1986年 | 26497篇 |
1985年 | 25306篇 |
1984年 | 17910篇 |
1983年 | 15186篇 |
1982年 | 7832篇 |
1979年 | 15802篇 |
1978年 | 10598篇 |
1977年 | 9052篇 |
1976年 | 7871篇 |
1975年 | 8628篇 |
1974年 | 10466篇 |
1973年 | 9858篇 |
1972年 | 9357篇 |
1971年 | 8852篇 |
1970年 | 8426篇 |
1969年 | 7923篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
61.
Weiyu Ye Anna Olsson-Brown Robert A. Watson Vincent T. F. Cheung Robert D. Morgan Isar Nassiri Rosalin Cooper Chelsea A. Taylor Umair Akbani Oliver Brain Rubeta N. Matin Nicholas Coupe Mark R. Middleton Mark Coles Joseph J. Sacco Miranda J. Payne Benjamin P. Fairfax 《British journal of cancer》2021,124(10):1661
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma 相似文献
62.
63.
64.
65.
66.
67.
目的 探讨剂量组学在预测肺癌根治性放疗患者放射性肺炎发生中的应用潜能。方法 回顾性收集行根治性放疗的314例肺癌患者的临床资料、放疗剂量文件、定位及随访CT图像,根据临床资料及影像学随访资料对放射性肺炎进行分级,提取全肺的剂量组学特征,构建机器学习模型。应用1000次自助抽样法(bootstrap)的最小绝对值收敛和选择算子嵌套逻辑回归(LASSO‐LR)及1000次bootstrap的赤池信息量准则(AIC)向后法筛选与放射性肺炎相关的剂量组学特征,随机按照7∶3划分为训练集及验证集,应用逻辑回归建立预测模型,并应用ROC曲线及校正曲线评价模型的性能。结果 共提取120个剂量组学特征,经LASSO‐LR降维筛选得到12个特征进入“特征池”,再经过AIC向后法筛选,最终筛选出6个剂量组学特征进行模型构建,训练集AUC为0.77(95%CI为0.65~0.87),独立验证集AUC为0.72(95%CI为0.64~0.81)。结论 利用剂量组学建立的预测模型具有预测放射性肺炎发生的潜力,但仍需继续纳入多中心数据及前瞻性数据进一步挖掘剂量组学的应用潜能。 相似文献
68.
69.
The serrated pathway (SP) can be viewed as two parallel, but partially overlapping, arrays of colorectal precursor lesions, and their respective endpoint carcinomas, that are distinct from those of the conventional adenoma–carcinoma sequence (APC‐pathway). In this review we focus at the outset on the clinical impact, pathological features, molecular genetics and biological behaviours of the various SP cancers. Then we summarize the clinicopathological features, classification and molecular profiles of the two main precursor lesions that anchor the respective pathways: (i) sessile serrated adenoma/polyp (SSA/P), also called sessile serrated lesion (SSL), and (ii) traditional serrated adenoma (TSA). Activating mutations of the RAS–RAF–MAPK pathway initiate and sustain the lesions of the SP, and CpG island methylation of the promoter regions of tumour suppressor and DNA repair genes play the major role in their neoplastic progression. The SP includes microsatellite stable (MSS) carcinomas that are among the most biologically aggressive colorectal carcinomas (CRC), and also accounts for the great preponderance of sporadic hypermutated, mismatch repair (MMR)‐deficient or microsatellite instable (MSI) CRC. The identification, removal and appropriate classification of at‐risk SP precursors and surveillance of individuals who harbour these lesions present a challenge and opportunity for CRC prevention and mortality reduction. 相似文献
70.
Fudaba M. Tachibana D. Misugi T. Nakano A. Koyama M. 《Journal of thrombosis and thrombolysis》2021,51(3):818-820
Journal of Thrombosis and Thrombolysis - Amniotic fluid embolism (AFE) is a catastrophic condition in the peripartum period and still remains as a leading cause of maternal death. Although over 80%... 相似文献